Objectives The METIMMOX 1 and 2 projects, led by Akershus University Hospital (AUH), constitute a pioneering clinical study investigating inoperable, metastatic, microsatellite-stable colorectal cancer. The study aimed to evaluate the efficacy, safety, and tolerability of sequentially adding immune-modulating therapy to standard chemotherapy. In collaboration with Oslo University Hospital, the project generated extensive and complex mass cytometry datasets to identify biomark

Objectives The OxyTarget clinical trial was conducted at Akershus University Hospital (AUH). This study attempted to establish a reliable method for detection of rectal cancer patients with aggressive tumors at risk of metastatic disease and death using an experimental functional MRI procedure. Blood samples were collected from 36 patients before undergoing neoadjuvant chemoradiotherapy and, eventually, surgery. Oslo University Hospital (OUH) performed mass cytometry experime